Opna Bio SA is a clinical stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics.

Opna Bio SA was founded to develop drugs aimed at disrupting the actions of an unprecedented new cancer target – fragile-X mental retardation protein (FMRP), as well as a rich pipeline of validated oncology drugs. In addition to its discovery-stage FMRP program, Opna’s lead clinical compound, OPN-2853, a bromo and extra terminal (BET) domain inhibitor, is currently in a Phase 1/2 trial with ruxolitinib (Jakafi®) in myelofibrosis, a chronic bone marrow disorder. The company also expects to initiate a Phase 2 study with OPN-7486, a colony stimulating factor 1 (CSF1) receptor inhibitor, in 2023.